TABLE 1 Results of a meta-analysis of clopidogrel
in women and men (42) Population Outcomes in women and men Various populations CV events including ACS and PCI (N = 79,613; women: Women: 11 % clopidogrel
The drug therapy includes daily aspirin and either clopidogrel
(Plavix) or prasugrel (Effient).
thienopyridines such as clopidogrel
and prasugrel) reduces platelet-rich thrombi that cause coronary artery stent thrombosis and recurrent acute coronary syndrome (ACS) (3) (i.
Two antiplatelet agents, aspirin and clopidogrel
(Plavix), are commonly given along with the anticoagulant warfarin (Coumadin) to patients with atrial fibrillation who have a heart attack or undergo stent placement.
Final results of the Clopidogrel
in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE) study, suggesting that a short course of dual antiplatelet therapy appears to be beneficial after stroke or transient ischemic attack (TIA), has now been published
Washington, June 27 ( ANI ): A simple drug regimen of two anti-clotting drugs - clopidogrel
and aspirin - can lower the risk of suffering a stroke by about one-third, a new clinical trail has showed.
Objectives: To evaluate Aspirin and Clopidogrel
resistance/non-responders in patients with acute coronary syndrome (ACS) by using adenosine diposphate and aspirin tests.
Aspirin and Extended-Release Dipyridamole versus Clopidogrel
for Recurrent StrokePrevention Regimen for Effectively Avoiding Second Strokes(PRoFESS) Study Group.
Daiichi Sankyo Company, Limited, and Eli Lilly and Company today announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel
plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an artery-opening procedure.
has a boxed warning to alert health care professionals and patients that the drug may not work well for those with certain genetic factors that affect how the body metabolizes the drug.
Sanjay Kaul said that the availability of generic clopidogrel
was welcome news "especially for cost-prohibitive environments, where affordability is a major detriment to long-term treatment adherence and, consequently, an optimal benefit-risk balance.
M2 PHARMA-May 21, 2012-Dr Reddy's launches Clopidogrel
Tablets, USP in US market(C)2012 M2 COMMUNICATIONS